Key result
Implantable cardioverter defibrillators and cardiac resynchronisation therapy reduce mortality and hospitalizations in selected patients with heart failure when used as adjuncts to medical therapy.
Why the study?
Do implantable cardioverter defibrillators and cardiac resynchronisation therapy improve outcomes in patients with heart failure?
Do implantable cardioverter defibrillators and cardiac resynchronisation therapy improve outcomes in patients with heart failure?
ICDs and CRT are effective adjuncts to guideline-directed medical therapy in heart failure management, reducing mortality and improving functional capacity.
Clinical trials have established the benefits of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) in the treatment of heart failure patients. As adjuncts to guideline-directed medical therapy, ICDs confer mortality benefits from sudden cardiac arrest, while CRT reduces mortality, hospitalisation rates and improves functional capacity. This review discusses the use of ICDs and CRT devices in heart failure management, outlining the evidence supporting their use, indications and contraindications.
No takes yet. Share an insight, caveat, or question.
Chia et al. (2016) conducted a review in Heart failure. Implantable cardioverter defibrillators and cardiac resynchronisation therapy vs. Guideline-directed medical therapy was evaluated. Implantable cardioverter defibrillators and cardiac resynchronisation therapy reduce mortality and hospitalizations in selected patients with heart failure when used as adjuncts to medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: